Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/35367
Title: | Lichen planus pemphigoides during therapy with tislelizumab and sitravatinib in a patient with metastatic lung cancer. | Authors: | Mar A. ;Kerkemeyer K.L.S.;Lai F.Y.X. | Monash Health Department(s): | Dermatology | Institution: | (Kerkemeyer, Lai, Mar) Department of Dermatology, Monash Health, Clayton, VIC, Australia | Issue Date: | 4-Jun-2020 | Copyright year: | 2020 | Publisher: | Blackwell Publishing | Place of publication: | Australia | Publication information: | Australasian Journal of Dermatology. 61 (2) (pp 180-182), 2020. Date of Publication: 01 May 2020. | Journal: | Australasian Journal of Dermatology | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/ajd.13214 | PubMed URL: | 31808542 [http://www.ncbi.nlm.nih.gov/pubmed/?term=31808542] | ISSN: | 0004-8380 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/35367 | Type: | Letter | Subjects: | betamethasone sitravatinib tislelizumab [Adverse Drug Reaction] tislelizumab lichen planus pemphigoides erythema histopathology immunofluorescence test inflammatory infiltrate lichen planus lung adenocarcinoma maculopapular rash metastasis multiple cycle treatment parakeratosis pruritus rash stria betamethasone betamethasone/tp [Topical Drug Administration] complement component C3 emollient agent emollient agent/tp [Topical Drug Administration] immunoglobulin G pembrolizumab [Adverse Drug Reaction] pembrolizumab prednisolone [Oral Drug Administration] prednisolone sitravatinib sitravatinib [Oral Drug Administration] acanthosis aged blister drug withdrawal |
Type of Clinical Study or Trial: | Case series or case report |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.